Front. Cardiovasc. Med. Frontiers in Cardiovascular Medicine Front. Cardiovasc. Med. 2297-055X Frontiers Media S.A. 10.3389/fcvm.2022.861798 Cardiovascular Medicine Systematic Review Association Between Asthma and All-Cause Mortality and Cardiovascular Disease Morbidity and Mortality: A Meta-Analysis of Cohort Studies Zhang Bin 1 † Li Zhi-Fei 2 † An Zhuo-Yu 3 † Zhang Li 2 Wang Jing-Yi 2 Hao Meng-Di 2 Jin Yi-Jing 4 Li Dong 5 Song An-Jian 1 Ren Qiang 1 Chen Wen-Biao 6 * 1Department of Cardiovascular Disease and Clinical Experimental Center, Jiangmen Central Hospital, Jiangmen, China 2Aerospace Center Hospital, Beijing, China 3Peking University People's Hospital, Beijing, China 4Peking University First Hospital, Beijing, China 5Department of Intensive Care Unit and Clinical Experimental Center, Jiangmen Central Hospital, Jiangmen, China 6Department of Respiratory Medicine, People's Hospital of Longhua, The Affiliated Hospital of Southern Medical University, Shenzhen, China

Edited by: Rajeev Gupta, Mediclinic, United Arab Emirates

Reviewed by: Jayadevan Sreedharan, Gulf Medical University, United Arab Emirates; Tiny Nair, PRS Hospital, India

 *Correspondence: Wen-Biao Chen chanwenbiao@sina.com

This article was submitted to Cardiovascular Epidemiology and Prevention, a section of the journal Frontiers in Cardiovascular Medicine

†These authors have contributed equally to this work and share first authorship

 17 03 2022 2022 9 861798 25 01 2022 16 02 2022 Copyright © 2022 Zhang, Li, An, Zhang, Wang, Hao, Jin, Li, Song, Ren and Chen. 2022 Zhang, Li, An, Zhang, Wang, Hao, Jin, Li, Song, Ren and Chen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 Background

Asthma and cardiovascular disease (CVD) share many risk factors. Previous meta-analyses indicated that asthma is associated with an increased risk of CVD and all-cause mortality, but these studies were limited by unstandardized search strategies and the number of articles included.

 Objective

We sought to systematically synthesize evidence investigating the impact of asthma on all-cause mortality and CVD morbidity and mortality.

 Methods

We searched in PubMed and EMBASE for observational cohort studies (inception dates to November 10, 2021) that had both asthma groups and control groups. We also manually searched the reference lists of correlative articles to include other eligible studies. Data for associations between asthma and all-cause mortality and CVD morbidity and mortality were needed.

 Results

We summarized the findings from 30 cohort studies comprising 4,157,823 participants. Asthma patients had increased CVD morbidity [relative risk (RR) = 1.28, 95% confidence interval (CI) = 1.16–1.40] and increased CVD mortality (RR = 1.25, 95% CI = 1.14–1.38). Asthma patients also had increased risk of all-cause mortality (RR = 1.38, 95% CI = 1.07–1.77). In subgroup analyses, female asthma patients had a higher risk of CVD morbidity and all-cause mortality than male asthma patients, and late-onset asthma patients had a higher risk of CVD morbidity than early-onset asthma patients.

 Conclusion

Asthma patients have increased risk of all-cause mortality and CVD morbidity and mortality. This information reminds clinicians to be aware of the risk of CVD and all-cause mortality in asthma patients.

 Systematic Review Registration

http://www.crd.york.ac.uk/PROSPERO/, PROSPERO, identifier: CRD 42021290082.

 asthma cardiovascular disease cardiovascular disease morbidity cardiovascular disease mortality all-cause mortality Introduction

Asthma is the most common inflammatory chronic non-infectious pulmonary disease in adults and children, and is estimated to affect 334 million people worldwide (1). Asthma is more common in developed countries and imposes a serious health and economic burden worldwide (2, 3). Chronic airway inflammation and airway hyperresponsiveness are the main pathophysiological features of asthma, which manifests as progressive airway remodeling (4, 5). The pathogenesis of asthma involves immune-inflammatory mediators and neuromodulator mechanisms (6). Asthma and cardiovascular disease (CVD) share many risk factors, such as inflammation (7). Patients with asthma suffer from a chronic inflammatory state, and asthma patients have been shown to have persistently elevated levels of inflammatory factors, such as fibrinogen and tumor necrosis factor-1 (8). In addition, poor lung function and eosinophilia, which are characteristic of asthma, have been shown to be predictors of cardiovascular mortality (9–11).

As asthma is very common and the consequences of CVD are critical, understanding their relationship will provide useful information to clinicians treating patients with asthma. Moreover, the long-term prognosis of asthma patients is one of the crucial questions that need to be addressed in this field. Understanding the impact of asthma on long-term mortality and cardiovascular risk and mortality is important for the development of clinical practice guidelines.

Previous meta-analyses have indicated that asthma is associated with an increased risk of CVD and all-cause mortality, but these studies were limited by unstandardized search strategies and a failure to include recent, updated articles (12–14). To overcome these limitations and provide reliable conclusions, we conducted a systematic evaluation and meta-analysis to investigate the impact of asthma on all-cause mortality and CVD morbidity and mortality.

 Materials and Methods

We conducted this meta-analysis following Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines (15) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Supplementary Table 3). The meta-analysis was registered with the International Prospective Register of Systematic Reviews (PROSPERO identifier: CRD 42021290082).

Literature Search

We searched PubMed and Embase for cohort studies from inception to November 10, 2021, without language restrictions. See the Supplementary File for search details (Supplementary Table 1). We also included other eligible studies by manually searching the reference lists of former similar meta-analyses and relevant studies.

 Eligibility Criteria

We included only observational cohort studies without publication time restriction. Both retrospective and prospective cohort studies were included if they had both asthma groups and control groups. Theoretically, in included studies, the difference between asthma groups and control groups should only be whether they had asthma or not. We excluded studies which only included specific asthma patients such as having ICS treatment or overlapping chronic obstructive pulmonary disease. To assess comparability between the asthma groups and the control groups, we included studies that provided baseline characteristics of the population. Outcome measures on the association between asthma and all-cause mortality or CVD morbidity and mortality were necessary. The total number of subjects in the studies must be >1,000 to reduce bias.

 Data Extraction

A data collection table was made in advance. The correlative data were extracted by two investigators (Z-FL and Z-YA) independently. When there was disagreement, a third person (BZ) would assist in the discussion and make the final decisions. Any collected data were aggregate, and no individual-level data were included.

 Quality Assessment

The risk of bias and quality of studies were evaluated by the Newcastle-Ottawa Scale (NOS) for cohort studies. The NOS ranges from 0 to 9 points. When the NOS is <6 points, the study would be regarded low quality; 6 or 7 points, the study would be regarded medium quality; and more than 7 points, the study would be regarded high quality. Two authors (LZ and J-YW) finished the quality evaluation. When there was disagreement, a third person (BZ) would assist in the discussion and make the final decisions.

 Outcomes of Interest

Data for associations between asthma and all-cause mortality and CVD morbidity and mortality were needed, such as relative risk (RR), hazard ratios (HRs), or number of CVD events (morbidity, mortality) or all-cause deaths in the asthma and control groups.

 Statistical Analysis

At first, we measured both adjusted and unadjusted RRs/HRs. Then, we pooled the adjusted RRs that were initially provided in the studies or estimated by the HRs. I2 statistic were used to evaluate the heterogeneity of included studies. when I2 >50%, significant heterogeneity was considered existing (16) and the random-effects model was used. Funnel plots were used to evaluate publication bias. RevMan 5.4.1 (Nordic Cochrane Center, Cochrane Collaboration) were used to conduct all calculations and draw forest plots to show the results. Stata version 14.0 (Stata Corp., College Station, TX, USA) were used for sensitivity analysis.

 Results

Thousand thirty nine studies were yielded by the electronic search of Pubmed and Embase databases and manual search. After applying the inclusion and exclusion criteria, 30 studies (17–46) were included in the meta-analysis, including 5 studies (42–46) assessed from the manual search and 25 studies (17–41) from the electronic database search (Figure 1).

Flow chart of article selection process.

 Description of Studies

All 30 studies were observational cohort studies, including 25 prospective cohort studies and 5 retrospective cohort studies. We collected the baseline characteristics of each study (Table 1). These studies comprised 4,157,823 participants. Thirteen studies were done in Europe, 12 in North America, 3 in Oceania, and 2 in Asia. In our quality assessment used the NOS (Supplementary Table 2), 17 studies were regarded as high quality, 13 as medium quality, and none as low quality. Nine studies included male and female subgroups. Three studies included early and late-onset asthma subgroups.

Baseline characteristics of participants assessed in the studies included in the meta-analysis.

Study authors, year of publication, location Total Define of cardiovascular diseases Confounding factors adjusted for in the analyses NOS score
Population Participant number Study type Follow-up, mean or (range) Age, range or (mean ±SD) Gender (female, %) diagnosis criteria of asthma Comorbidities, n (%)
Ingebri et al. (42), 2020, Denmark community 44,177 prospective 5.7 57.9 ± 11.0 61% Self-reported DM:2.8% CHD, HF Age, gender, family history of CVD, smoking, BMI, HTN, DM, TC levels and physical activity in leisure time 8
Bellia et al. (44), 2007, Italy hospital 1,233 prospective 4.8 >65 53% Doctor diagnosis CVD:15.7% CBVD:6.0% DM:12.2% NA Age, gender, smoking habit, physical and cognitive, mood status, FEV1%, FVC%, FEV1/FVC, BMI, Charlson index of comorbidity, SGRQ, inhaled CS or β2adrenergic drugs 8
Liss et al. (45), 2000, Canada hospital 2,400 prospective 8 17–65 40% Doctor diagnosis NA IHD Period of birth, time period of accident, sex 6
Çolak et al. (46), 2015, Denmark community 42,489 prospective 4.5 20-100 59% Self-reported NA IHD NA 7
Lange et al. (19),1996,Denmark community 13,540 prospective 17 >20 55% Self-reported NA ICD-8 (390-459) Age, asthma, smoking habits, inhalation habits, length of school education, chronic mucus hypersecretion 8
Ali et al. (29), 2013, Denmark community 2,150 prospective 25.6 >15 60% Doctor diagnosis NA ICD-10 (DI20) Age, FEV1% 8
Dantzer et al. (21), 2001, France community 2,348 prospective 8 >65 59% Self-reported NA NA Sex, educational level, marital status, cognitive impairment, smoking and a previous history of IHD, infarcts and cardiovascular accident. 7
Diaz-Guzman et al. (26), 2011, America community 15,203 prospective 18 >25 53% Self-reported NA NA Age, sex, race/ethnicity, smoking status, education level, BMI, reported respiratory disease and disease stage 7
Huovinen et al. (20), 1997, Finland community 30,249 prospective 16 >18 51% Doctor diagnosis NA NA Age, smoking, social class, pets, dogs, CB, dyspnea, hay fever 9
Markowe et al. (17), 1987, England and Wales community 5,094 prospective 8.4 25-64 55% Doctor diagnosis NA ICD-8 (390-459) NA 8
Ulrik and Frederiksen (18), 1995, Denmark outpatient 2,150 prospective 8.6 >15 60% Doctor diagnosis NA ICD-8(410) NA 8
Vandentorren et al. (22), 2003, France community 1,4267 retrospective 25 25-59 52% Self-reported NA NA Age, sex, educational level, smoking habits, occupational exposure, FEV1 8
Chung et al. (30), 2014, China community 38,840 prospective 1-−20 ≥18 54% Doctor diagnosis HTN:32.5% DM:11.6% HPL:16.6% Stroke:8.7% HF:2.4% COPD:27.1% ACS Age, sex, comorbidities of HTN, DM, HPL, stroke, HF and COPD 8
Iribarren et al. (23), 2004, America community 151,620 retrospective 27 15-92 54% Doctor diagnosis HTN:18.5% DM:18.0% CHD Age, race/ethnicity, education level, smoking Status, alcohol consumption, BMI, serum TC, white blood cell count, HTN, DM, parental history of CHD, and occupational exposures. 7
Iribarren et al. (27), 2012, America community 407,190 prospective 5.2-6.3 ≥18 52% Doctor diagnosis HTN:7.2% DM:5.6% HPL:6.1% CHD DM, HTN, HPL, BMI, and smoking status, prior history of any allergy 7
Onufrak et al. (25), 2008, America community 14,567 prospective 12-14 45-64 54% Self-reported DM:10.9% HTN:33.5% CB:8.4% CHD Age, BMI, black race, DM, HTN, education level, LDL-C, HDL-C, physical activity 8
Schanen et al. (24), 2005, America community 1,3797 prospective 14 45-64 57% Self-reported HTN:23.0% DM:10.4% CHD Age, sex, race/center, HDL-C, LDL-C, systolic blood pressure, HTN medication use, smoking status, pack years, W/H ratio, DM, sport score 7
Yun et al. (28), 2012, America community 7,176 retrospective Asthma:2.9-13.2, control:1.9-12 15.1 ± 20.5 43% Doctor diagnosis NA CHD Race/ethnicity (white vs. non-white) 7
Ng, et al. (43), 2020, Australia school 4,430 retrospective 16 11.8 ± 2.9 50% Self-reported NA NA Birth year, age at child survey, and gender 7
Eftekhari, et a. (33), 2016, Australia community 10,413 prospective 11.9 73-78 100% Self-reported HTN:33.0%, DM:7.3%, heart disease:13.1%, thrombosis:1.5%, stroke:2.7% NA Age, demographic factors, thrombosis, osteoporosis, low iron level, HTN, DM, breast cancer, stroke, other major illness, residential area, social support 8
Strand, et al. (36), 2018, China community 446,346 prospective 17 40.0 ± 13.5 51% Self-reported HTN:18.2%, DM:5.0%, heart disease/heart surgery/use of heart drugs:3.6%, stroke:0.5% CHD, stroke Age, education, marital status, smoking, alcohol consumption, physical activity, DM, HTN, BMI, TC, TG, history of heart disease/heart surgery/use of heart drugs and history of stroke. 7
Lemmetyinen et al. (35), 2018, Finland community 2,941 prospective 15.6 >30 50% Doctor diagnosis and self-reported Allergic rhinitis:36.2%, Allergic conjunctivitis:27.6%, Atopic dermatitis:27.6% ICD-10 (I05-I99) Age, sex, pack-years, education, and BMI 8
Cepelis et al. (37), 2019, Norway community 57,104 prospective 17.2 >20 54% Self-reported DM:2.2%, HTN:37.5% AMI Age, sex, BMI, smoking status, alcohol use, physical activity, education level, TC/HDL ratio, HTN, DM 8
Caffrey Osvald et al. (38), 2020, Sweden community 277,5430 retrospective 13.7 1-27 49% Doctor diagnosis NA NA Sex, prematurity, maternal age at delivery, maternal smoking during pregnancy, maternal country of birth, parental income, parental education 8
He et al. (40), 2021, America community 37,015 prospective 7.5 >20 52% Self-reported DM:8.8%, CHD:3.3%, stroke:2.7%, cancer:9.3%, arthritis:24.1% NA Age, sex, race, education, income, smoking status, BMI, DM, arthritis, CHD, stroke, cancer 7
Huang et al. (31), 2015, America community 1,830 prospective 40 21-80 56% Doctor diagnosis NA NA Age, sex, education, BMI, smoking status and pack-years 8
Pollevick et al. (41), 2021, America community 3,612 prospective 35 17-77 53% Doctor diagnosis DM:2.4% MI, angina, coronary insufficiency, stroke transient ischemic attack, HF Age, sex, HDL-C, TC, currently taking anti-HTN medications, systolic blood pressure, DM, currently smoking, obesity, and education 8
Ng et al. (39), 2021, Australia school 2,153 prospective 20.2 32.4 50% Doctor diagnosis and self-reported DM:2.5%, history of hay fever:33.0% ICD-9 (390-459), ICD-10 (I00-99, G45) Birth year, age at child survey, and gender 7
Tattersall et al. (34), 2016, America employees 1,267 prospective 13.9 47.3 ± 8.0 44% self-reported HTN:29.4%, DM:3.0% coronary death, MI, angina, stroke, coronary revascularization, HF Age, sex, smoking status, DM, lipid medications, HTN, BMI 7
Tattersall et al. (32), 2015, America community 6,792 prospective 9.1 62.2 ± 10.3 52% self-reported DM:12.6% CHD, stroke, angina Age, race, sex, TC, HDL-C, systolic blood pressure, smoking, DM, anti-HTN and lipid-lowering medication use at baseline, BMI, family history of CVD, income 8
Association Between Asthma and All-Cause Mortality

Using the random-effects model, we analyzed 18 studies that included 20 subgroups (Figure 2). Asthma patients had a 38% increased risk of death compared to people without asthma (RR = 1.38, 95% CI = 1.07–1.77, p = 0.01, I2 = 98%, p < 0.00001). Though considerable heterogeneity existed, most studies or subgroups (16 in 20) indicated an increased risk of mortality in asthma patients. We also found high heterogeneity, mainly because a large-scale study (27) conducted by Iribarren et al. in 2012 reported an outlier HR (3.28, 95% CI = 3.15–3.41).

Forest plot shows association between asthma and all-cause mortality. SE, standard error; IV, Inverse Variance method; df, degrees of freedom; int, intermittent; per, persistent.

Five studies were included in the subgroup analysis of male and female patients using the random-effects model (Figure 3). In male asthma patients, risk of all-cause mortality increased 52% compared to people without asthma, though this difference was not significant (RR = 1.52, 95% CI = 0.88–2.62, p = 0.13; I2 = 98%, p < 0.00001). In female patients, risk of all-cause mortality increased 90% compared to people without asthma (RR = 1.90, 95% CI = 1.20–3.00, p = 0.006; I2 = 96%, p < 0.00001).

Forest plot shows association between asthma and all-cause mortality in male and female patients. SE, standard error; IV, Inverse Variance method; df, degrees of freedom.

 Association Between Asthma and CVD Morbidity

We analyzed 14 studies with a total of 24 subgroups (Figure 4). The random-effects model showed that asthma patients had a 32% increased risk of CVD compared to people without asthma (RR = 1.28, 95% CI = 1.16–1.40, p < 0.00001; I2 = 85%, p < 0.00001). Thus, asthmatic status increases the risk of CVD morbidity.

Forest plot shows association between asthma and CVD morbidity. SE, standard error; IV, Inverse Variance method; df, degrees of freedom; HF, heart failure; CHD, coronary heart disease; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male; int, intermittent; per, persistent.

In the subgroup analysis of early and late-onset asthma using the fixed-effects model, three studies had a total of five subgroups (Figure 5). One study (34) defined early-onset as asthma onset prior to 18 years and late-onset as asthma onset at 18 years or older. The other two studies (25, 42) applied the cutoffs of 40 years and 21 years. Early-onset asthma patients has a 26% increased risk of CVD compared to people without asthma (RR = 1.26, 95% CI = 1.02–1.55, p = 0.03; I2 = 46%, p = 0.12). Late-onset asthma patients had a 39% increased risk of CVD compared to people without asthma (RR = 1.39, 95% CI = 1.17–1.66, p = 0.0002; I2 = 37%, p = 0.17). This subgroup analysis reduced the heterogeneity of studies.

Forest plot shows association between asthma and CVD morbidity in early and late-onset asthma patients. SE, standard error; IV, Inverse Variance method; df, degrees of freedom; HF, heart failure; CHD, coronary heart disease; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male.

In the subgroup analysis of male and female patients using the random-effects model, five studies had a total of six subgroups (Figure 6). Male asthma patients had an 18% higher risk of CVD morbidity compared to people without asthma (RR = 1.19, 95% CI = 1.00–1.41, p = 0.05; I2 = 88%, p < 0.00001). Female asthma patients had a 37% higher risk of CVD compared to people without asthma (RR = 1.39, 95% CI = 1.20–1.61, p < 0.00001; I2 = 83%, p < 0.0001).

Forest plot shows association between asthma and CVD morbidity in male and female asthma patients. SE, standard error; IV, Inverse Variance method; df, degrees of freedom; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male.

 Association Between Asthma and CVD Mortality

Nine studies provided the outcomes of CVD mortality in asthma patients. These studies were summarized for the first time (Figure 7). Data calculated by the fixed-effects model showed that asthma patients have a 25% increased risk of CVD mortality compared to people without asthma (RR = 1.25, 95% CI = 1.14–1.38, p < 0.00001). There was no considerable heterogeneity between these studies (I2 = 13%, p = 0.32). Eight of nine studies yielded an increased risk of CVD mortality in asthma patients. Six of nine studies were regarded as high quality.

Forest plot shows association between asthma and CVD mortality. SE, standard error; IV, Inverse Variance method; df: degrees of freedom.

 Sensitivity Analysis

We conducted sensitivity analysis to examine the robustness of the meta-analyses by omitting each study in turn and recalculating the pooled effect estimates (Supplementary Figures 4–12). In male asthma patients, one study (27) altered the significantly increased risk of all-cause mortality to no significant difference. However, this study did not change the estimate significantly. Two subgroups of two studies (25, 42) decreased the estimate of CVD morbidity in early-onset asthma patients significantly (Supplementary Figure 9). However, this may due to that two studies did not provide the overall estimate, and we input the grouping estimate (male, female and CHD, HF) provided by the studies. Overall mortality analysis has a I square of 98% (highly heterogenous), and we conducted sensitivity analysis by omitting two outliers [Colak et al. (46) and Iribarren et al. (27)] and result still robust (Supplementary Figure 13).

 Publication Bias

Publication bias was evaluated using funnel plots, and no clear asymmetry was found by visual inspection (Supplementary Figures 1–3). We noted that one study (27) had relatively high loss to follow-up (24% of asthma subjects, 10% of control subjects) and had a significant outlier outcome (Supplementary Figure 3). Overall, no significant publication bias was found among the included observational cohort studies.

 Discussion

In this systematic review, we found that asthma patients have a significantly increased risk of CVD morbidity and mortality and all-cause mortality. Male asthma patients had no significant increased risk of all-cause mortality, and lower risk of CVD morbidity and all-cause mortality than female asthma patients. In addition, early-onset asthma patients had a lower risk of CVD morbidity than late-onset asthma patients.

Association Between Asthma and All-Cause Mortality

Finding that asthma patients have an increased risk of all-cause mortality confirms the results of a previous meta-analysis (14). However, a large-scale study (27) reporting a considerably high risk of all-cause mortality is the main reason for heterogeneity between studies and the most conspicuous outlier in the funnel diagram. We considered two main reasons for this outlier outcome. First, high loss to follow-up can bias the results. Second, the inclusion criteria for asthma patients were one hospitalization, two outpatient visits, or two emergency department visits for asthma within 12 months, whereas most of the other studies based the inclusion criteria on questionnaires about self-reported asthma history. Thus, all of the asthma patients in that study had active and more severe asthma and, therefore, higher CVD morbidity and mortality risk than non-active asthma patients (37, 40).

Though asthma patients have an increased risk of all-cause mortality, only a small number of asthma patients die directly from asthma itself (35). Thus, an increased risk of death in asthma patients is mainly due to comorbidities. Asthma patients always have chronic inflammation and airway limitations, which can elevate the risk of chronic obstructive pulmonary disease (COPD) and type 2 diabetes (47). In addition, asthma medication can cause comorbidities. Inhaled corticosteroids may be related to osteoporosis, increased fracture risk, and pneumonia (48). Inhaled β2-agonist can increase the risk of CVD (49). Furthermore, suboptimal asthma control can limit physical activity and cause poor sleep quality, which could contribute to obesity, depression, and osteoporosis. All of these comorbidities can increase mortality in patients with asthma (48).

Subgroup analyses showed that male asthma patients have no significantly increased risk of all-cause mortality. We found the negative outcome in male asthma patients mainly because the large-scale study (27) provided a high outlier HR value with small CI. It broadened the CI for the all-cause mortality estimate in male asthma patients so that there was no significant increase. As mentioned above, patients in this large-scale study (27) had active and more severe asthma, which resulted in the high outlier RR value. The other four studies in this subgroup analysis relied on exposure history of asthma, which also includes non-active or mild asthma patients. However, sensitivity analysis showed that this study did not significantly increase the estimate. Therefore, we still concluded that male asthma patients have a 52% increase in all-cause mortality, though this difference was not significant.

 Association Between Asthma and CVD Morbidity and Mortality

We found that asthma patients have a increased risk of CVD morbidity and mortality than people without asthma. Finding an increased risk of CVD morbidity in asthma patients is consistent with a previous meta-analysis (13, 14, 50). The biological mechanism by which asthma causes and aggravates CVD is still unclear. However, some mechanisms have been suggested. First, asthma and CVD share some risk factors, such as smoking and chronic inflammation (7, 51). Asthma can cause inflammation not only in the airway, but also in the whole body (systemic). Prior studies found that colchicine can reduce the incidence rate of CVD to 69%, strongly suggesting that inflammation takes part in the start and progression of CVD (52). Second, asthma patients have an increased risk of chronic airflow obstruction, which can cause lung function decline (53). Impaired lung function is associated with increased levels of inflammatory biomarkers in the circulation (54) and inflammation. Third, asthma medication can cause CVD. Inhaled β2-agonists are associated with an increased risk of adverse cardiovascular outcomes (49).

Subgroup analyses indicate that both male and female asthma patients have a significantly increased risk of CVD morbidity. This outcome is in contrast to a previous meta-analysis (13, 14) that found no significantly increased risk of CVD morbidity in male asthma patients. Our finding confirmed that asthma patients have a significantly increased risk of CVD morbidity, regardless of gender. However, we noted that female asthma patients suffer from a higher increased risk of CVD morbidity than male asthma patients (39 vs. 19%). This gender difference may be associated with sex hormone. Some studies found that estrogen can cause low levels of systemic inflammation by modulating the release of proinflammatory cytokines and regulating the production of leukotrienes. In contrast, androgen may have anti-inflammation effects and protect against airway inflammation (25). As mentioned above, chronic inflammation is one of the risk factors for CVD. Therefore, for women, asthmatic state and estrogen effects can cause increased CVD risk through chronic inflammation.

Subgroup analyses showed that both early and late-onset asthma patients have a significantly increased risk of CVD morbidity. However, late-onset asthma patients have a higher increased risk than early-onset asthma patients (39 vs. 26%). Early and late-onset asthma patients may have different epidemiological characteristics. Most early-onset asthma cases are caused by allergy, whereas late-onset asthma has a complex etiology, such as smoking, occupational, and non-allergic sensitizers, which are related to CVD risk. Moreover, CVD generally occurs among the elderly. Studies of early-onset asthma had difficulties in following participants until their elderly years, which means that their follow-up was relatively insufficient to meet the outcomes of CVD.

 Limitations

The conclusions gained from this study are weakened by the inherent limitations of meta-analyses and observational cohort studies. Although most studies included reported adjusted estimates, the confounding factors of each study were not exactly the same. In addition, some of studies did not adjust for confounding factors. This led to an increased risk of bias in our meta-analysis. Furthermore, most estimates had high heterogeneity, probably because the population characteristics, diagnostic criteria for asthma, and definition of CVD in each study were not completely identical. Finally, all the included data were aggregate, and no individual-level data were available.

 Conclusion

Our study provides evidence that asthma patients have increased risk of all-cause mortality and CVD morbidity and mortality. In addition, subgroup analyses showed that female asthma patients have a higher risk of all-cause mortality and CVD morbidity, and that late-onset asthma patients have higher risk of CVD morbidity. This information reminds clinicians to be aware of the risk of CVD and all-cause mortality in asthma patients.

 Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

 Author Contributions

Z-FL: analysis of data, interpretation results, and drafting and editing the article. BZ, Z-YA, DL, A-JS, QR, and W-BC: design of study, solution of problem, and reviewing the article. LZ, J-YW, M-DH, and Y-JJ: extraction of data and assessment of articles quality. All authors contributed to the article and approved this version of article.

 Funding

The study was financially supported by the Youth Project of Guangdong Provincial Medical Research Fund (Grant No. B2021353), Outstanding Youth Fund Projects of Jiangmen Central Hospital (Grant Nos. J202101 and J202003), the project of Fundamental Research Funds of Jiangmen Central Hospital (Grant No. D201901), and the projects of Jiangmen City Science and Technology Plans (Grant Nos. 2021YLA01033, 2020YLA100, and 2020YLA133).

 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.861798/full#supplementary-material

Funnel plot depicting publication bias for the association between asthma and CVD morbidity. SE, standard error; RR, relative risk.

Funnel plot depicting publication bias for the association between asthma and CVD mortality. SE, standard error; RR, relative risk.

Funnel plot depicting publication bias for the association between asthma and all-cause mortality. SE, standard error; RR, relative risk.

Sensitivity analysis of association between asthma and CVD morbidity. CI, confidential interval; HF, heart failure; CHD, coronary heart disease; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male; int, intermittent; per, persistent.

Sensitivity analysis of association between asthma and CVD mortality. CI, confidential interval.

Sensitivity analysis of association between asthma and all-cause mortality. CI, confidential interval; int, intermittent; per, persistent.

Sensitivity analysis of association between asthma and all-cause mortality in male patients. CI, confidential interval.

Sensitivity analysis of association between asthma and all-cause mortality in female patients. CI, confidential interval.

Sensitivity analysis of association between asthma and CVD morbidity in early-onset patients. CI, confidential interval; HF, heart failure; CHD, coronary heart disease; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male.

Sensitivity analysis of association between asthma and CVD morbidity in late-onset patients. CI, confidential interval; HF, heart failure; CHD, coronary heart disease; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male.

Sensitivity analysis of association between asthma and CVD morbidity in male patients. CI, confidential interval; a/f, adult female; a/m, adult male; c/f, child female; c/m, child mal.

Sensitivity analysis of association between asthma and CVD morbidity in female patients. CI, confidential interval; a/f, adult female; a/m, adult male; c/f, child female; c/m, child male.

Sensitivity analysis of association between asthma and all-cause mortality by omitting two outliers. CI, confidential interval; int, intermittent; per, persistent.

Search strategies.

Newcastle-ottawa scale for assessing the quality of included studies.

PRISMA 2009 checklist.

 References Vos T Flaxman AD Naghavi M Lozano R Michaud C Ezzati M . Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. (2012) 380:2163–96. 10.1016/S0140-6736(12)61729-223245607 Asher MI Montefort S Björkstén B Lai CK Strachan DP Weiland SK . Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. (2006) 368:733–43. 10.1016/S0140-6736(06)69283-016935684 To T Stanojevic S Moores G Gershon AS Bateman ED Cruz AA . Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. (2012) 12:204. 10.1186/1471-2458-12-20434625037 Holgate ST Wenzel S Postma DS Weiss ST Renz H Sly PD. Asthma. Nat Rev Dis Primers. (2015) 1:15025. 10.1038/nrdp.2015.2527189668 Papi A Brightling C Pedersen SE Reddel HK. Asthma. Lancet. (2018) 391:783–800. 10.1016/S0140-6736(17)33311-129273246 Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. (2015) 5(Suppl. 1):S2–6. 10.1002/alr.2160926335832 Guite HF Dundas R Burney PG. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax. (1999) 54:301–7. 10.1136/thx.54.4.30110092690 Halasz A Cserhati E Magyar P Kovacs M Cseh K. Role of TNF-alpha and its 55 and 75 kDa receptors in bronchial hyperreactivity. Respir Med. (2002) 96:262–7. 10.1053/rmed.2001.125612000006 Barr RG Cooper DM Speizer FE Drazen JM Camargo CA. beta-Adrenoceptor polymorphism and body mass index are associated with adult-onset asthma in sedentary but not active women. Chest. (2001) 120:1474–9. 10.1378/chest.120.5.147411713122 Guerra S Sherrill DL Bobadilla A Martinez FD Barbee RA. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest. (2002) 122:1256–63. 10.1378/chest.122.4.125612377850 Hospers JJ Rijcken P Schouten JP Postma DS Weiss ST. Eosinophilia and positive skin tests predict cardiovascular mortality in a general population sample followed for 30 years. Am J Epidemiol. (1999) 150:482–91. 10.1093/oxfordjournals.aje.a01003710472948 Axson EL Ragutheeswaran K Sundaram V Bloom CI Bottle A Cowie MR . Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respir Res. (2020) 21:54. 10.1186/s12931-020-1312-732059680 Wang L Gao S Yu M Sheng Z Tan W. Association of asthma with coronary heart disease: a meta analysis of 11 trials. PLoS ONE. (2017) 12:e0179335. 10.1371/journal.pone.017933528609456 Xu M Xu J Yang X. Asthma and risk of cardiovascular disease or all-cause mortality: a meta-analysis. Ann Saudi Med. (2017) 37:99–105. 10.5144/0256-4947.2017.9928377538 Hutton B Salanti G Caldwell DM Chaimani A Schmid CH Cameron C . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. (2015) 162:777–84. 10.7326/M14-238526030634 Higgins JP Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. (2002) 21:1539–58. 10.1002/sim.118612111919 Markowe HL Bulpitt CJ Shipley MJ Rose G Crombie DL Fleming DM. Prognosis in adult asthma: a national study. Br Med J. (1987) 295:949–52. 10.1136/bmj.295.6604.9493119122 Ulrik CS Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. Chest. (1995) 108:10–5. 10.1378/chest.108.1.107606941 Lange P Ulrik CS Vestbo J. Mortality in adults with self-reported asthma. Copenhagen city heart study group. Lancet. (1996) 347:1285–9. 10.1016/S0140-6736(96)90937-X8622503 Huovinen E Kaprio J Vesterinen E Koskenvuo M. Mortality of adults with asthma: a prospective cohort study. Thorax. (1997) 52:49–54. 10.1136/thx.52.1.4933446724 Dantzer C Tessier JF Nejjari C Barberger-Gateau P Dartigues JF. Mortality of elderly subjects with self-reported asthma in a French cohort, 1991-1996. Eur J Epidemiol. (2001) 17:57–63. 10.1023/A:101099671800811523577 Vandentorren S Baldi I Annesi Maesano I Charpin D Neukirch F Filleul L . Long-term mortality among adults with or without asthma in the PAARC study. Eur Respir J. (2003) 21:462–7. 10.1183/09031936.03.0003030312662002 Iribarren C Tolstykh IV Eisner MD. Are patients with asthma at increased risk of coronary heart disease? Int J Epidemiol. (2004) 33:743–8. 10.1093/ije/dyh08115131088 Schanen JG Iribarren C Shahar E Punjabi NM Rich SS Sorlie PD . Asthma and incident cardiovascular disease: the atherosclerosis risk in communities study. Thorax. (2005) 60:633–8. 10.1136/thx.2004.02648416061703 Onufrak SJ Abramson JL Austin HD Holguin F McClellan WM Vaccarino LV. Relation of adult-onset asthma to coronary heart disease and stroke. Am J Cardiol. (2008) 101:1247–52. 10.1016/j.amjcard.2007.12.02418678319 Diaz-Guzman E Khosravi M Mannino DM. Asthma, chronic obstructive pulmonary disease, and mortality in the U.S population. COPD. (2011) 8:400–7. 10.3109/15412555.2011.61120022149399 Iribarren C Tolstykh IV Miller MK Sobel E Eisner MD. Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts. Am J Epidemiol. (2012) 176:1014–24. 10.1093/aje/kws18123139248 Yun HD Knoebel E Fenta Y Gabriel SE Leibson CL Loftus EV Jr . Asthma and proinflammatory conditions: a population-based retrospective matched cohort study. Mayo Clin Proc. (2012) 87:953–60. 10.1016/j.mayocp.2012.05.02022980164 Ali Z Dirks CG Ulrik CS. Long-term mortality among adults with asthma: a 25-year follow-up of 1,075 outpatients with asthma. Chest. (2013) 143:1649–55. 10.1378/chest.12-228923471206 Chung WS Shen TC Lin CL Chu YH Hsu WH Kao CH. Adult asthmatics increase the risk of acute coronary syndrome: a nationwide population-based cohort study. Eur J Intern Med. (2014) 25:941–5. 10.1016/j.ejim.2014.10.02325468246 Huang S Vasquez MM Halonen M Martinez FD Guerra S. Asthma, airflow limitation and mortality risk in the general population. Eur Respir J. (2015) 45:338–46. 10.1183/09031936.0010851425323227 Tattersall MC Guo M Korcarz CE Gepner AD Kaufman JD Liu KJ . Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. (2015) 35:1520–5. 10.1161/ATVBAHA.115.30545225908767 Eftekhari P Forder PM Majeed T Byles JE. Impact of asthma on mortality in older women: an Australian cohort study of 10,413 women. Respir Med. (2016) 119:102–8. 10.1016/j.rmed.2016.08.02627692129 Tattersall MC Barnet JH Korcarz CE Hagen EW Peppard PE Stein JH. Late-onset asthma predicts cardiovascular disease events: the wisconsin sleep cohort. J Am Heart Assoc. (2016) 5:e003448. 10.1161/JAHA.116.00344827559071 Lemmetyinen RE Karjalainen JV But A Renkonen RLO Pekkanen JR Toppila-Salmi SK . Higher mortality of adults with asthma: a 15-year follow-up of a population-based cohort. Allergy. (2018) 73:1479–88. 10.1111/all.1343129461632 Strand LB Tsai MK Wen CP Chang SS Brumpton BM. Is having asthma associated with an increased risk of dying from cardiovascular disease? a prospective cohort study of 446 346 Taiwanese adults. BMJ Open. (2018) 8:e019992. 10.1136/bmjopen-2017-01999229858410 Cepelis A Brumpton BM Laugsand LE Dalen H Langhammer A Janszky I . Asthma, asthma control and risk of acute myocardial infarction: HUNT study. Eur J Epidemiol. (2019) 34:967–77. 10.1007/s10654-019-00562-x31512117 Caffrey Osvald E Bower H Lundholm C Larsson H Brew BK Almqvist C. Asthma and all-cause mortality in children and young adults: a population-based study. Thorax. (2020) 75:1040–6. 10.1136/thoraxjnl-2020-21465532963117 Ng C Knuiman MW Murray K Divitini ML Musk AWB James AL. Childhood asthma increases respiratory morbidity, but not all-cause mortality in adulthood: the busselton health study. Respir Med. (2020) 171:106095. 10.1016/j.rmed.2020.10609532810754 He X Cheng G He L Liao B Du Y Xie X . Adults with current asthma but not former asthma have higher all-cause and cardiovascular mortality: a population-based prospective cohort study. Sci Rep. (2021) 11:1329. 10.1038/s41598-020-79264-433446724 Pollevick ME Xu KY Mhango G Federmann EG Vedanthan R Busse P . The relationship between asthma and cardiovascular disease: an examination of the framingham offspring study. Chest. (2021) 159:1338–45. 10.1016/j.chest.2020.11.05333316236 Ingebrigtsen TS Marott JL Vestbo J Nordestgaard BG Lange P. Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap. BMJ Open Respir Res. (2020) 7:e000470. 10.1136/bmjresp-2019-00047033371008 Ng C Knuiman MW Murray K Divitini ML Musk AWB James AL. Childhood asthma and cardiovascular morbidity and mortality in adulthood: the busselton health study. Pediatr Pulmonol. (2021) 56:1915–23. 10.1002/ppul.2538633819390 Bellia V Pedone C Catalano F Zito A Davi E Palange S . Asthma in the elderly: mortality rate and associated risk factors for mortality. Chest. (2007) 132:1175–82. 10.1378/chest.06-282417890479 Liss GM Tarlo SM Macfarlane Y Yeung KS. Hospitalization among workers compensated for occupational asthma. Am J Respir Crit Care Med. (2000) 162:112–8. 10.1164/ajrccm.162.1.990610810903229 Colak Y Afzal S Nordestgaard BG Lange P. Characteristics and prognosis of never-smokers and smokers with asthma in the copenhagen general population study. A prospective cohort study. Am J Respir Crit Care Med. (2015) 192:172–81. 10.1164/rccm.201502-0302OC25914942 Odegaard AO Jacobs DR Jr Sanchez OA Goff DC Jr Reiner AP Gross MD. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovasc Diabetol. (2016) 15:51. 10.1186/s12933-016-0369-627013319 Gershon AS Wang C Guan J To T. Burden of comorbidity in individuals with asthma. Thorax. (2010) 65:612–8. 10.1136/thx.2009.13107820627918 Au DH Curtis JR Every NR McDonell MB Fihn SD. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest. (2002) 121:846–51. 10.1378/chest.121.3.84611888971 Liu H Fu Y Wang K. Asthma and risk of coronary heart disease: a meta-analysis of cohort studies. Ann Allergy Asthma Immunol. (2017) 118:689–95. 10.1016/j.anai.2017.03.01228433577 Enright PL Ward BJ Tracy RP Lasser EC. Asthma and its association with cardiovascular disease in the elderly. The cardiovascular health study research group. J Asthma. (1996) 33:45–53. 10.3109/027709096090777628621370 Nidorf SM Fiolet ATL Mosterd A Eikelboom JW Schut A Opstal TSJ . Colchicine in patients with chronic coronary disease. N Engl J Med. (2020) 383:1838–47. 10.1056/NEJMoa202137232865380 James AL Palmer LJ Kicic E Maxwell PS Lagan SE Ryan GF . Decline in lung function in the busselton health study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med. (2005) 171:109–14. 10.1164/rccm.200402-230OC15486340 Tamagawa E van Eeden SF. Impaired lung function and risk for stroke: role of the systemic inflammation response? Chest. (2006) 130:1631–3. 10.1378/chest.130.6.163117166971 Abbreviations CVD

cardiovascular disease

 CI

confidential interval

 RR

relative risk

 HR

hazard ratio

 NOS

Newcastle-Ottawa Scale

 PRISMA

Preferred Reporting Items for Systematic Reviews and Meta-Analyses

 MOOSE

Meta-Analysis of Observational Studies in Epidemiology

 PROSPERO

Prospective Register of Systematic Reviews.